CompletedNCT00208169
Aripiprazole to reduce alcohol or drug use with co-occurring mental health conditions
About this title
Abilify Therapy for Reducing Comorbid Substance Abuse
Read the official source — NCT00208169Medication studyAges 19–65United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 19 years to 65 years.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- OmahaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Creighton University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT00208169
- Official title
Show the full official title
Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse
Get this study by email
Recruitment & locations
CompletedOmaha
Questions about this study
Who is behind this study?
The study sponsor is Creighton University, a university.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 19 years to 65 years.
